Articles tagged "Immunosuppression"

2018 American Transplant Congress
Pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19 and Their Influence on Tacrolimus Pharmacokinetics in Renal Transplant Recipients
Z. Wang, Z. Han, J. Tao, H. Chen, L. Sun, R. Tan, M. Gu.
Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Tacrolimus (TAC) is an established essential immunosuppressive agent for renal transplant recipients. Our study aims to investigate the pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19…
2018 American Transplant Congress
Impact of Once-Daily Tacrolimus on Adherence in Stable Adolescent and Young Adult Renal Transplant Recipients
M. Moss,¹ J. Goebel,² M. Bock.²
¹Pharmacy, Children's Hospital Colorado, Aurora, CO; ²Pediatric Nephrology, Children's Hospital Colorado, Aurora, CO.
Medication non-adherence is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs), especially adolescents and young adults (AYA). Number of medication…
2018 American Transplant Congress
Late Conversion from Calcineurin Inhibitors to Belatacept is Associated with a Sustained Improvement in Kidney Allograft Function
S. Sethi, J. Choi, A. Vo, R. Najjar, A. Peng, S. Jordan, E. Huang.
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Belatacept was shown to have longer kidney graft survival and higher eGFR at 7 years than a calcineurin inhibitor (CNI)-based regimen in the BENEFIT…
2018 American Transplant Congress
Cognition after Belatacept Conversion
C. Ogbejesi, E. Cohen, K. Belfield, W. Asch.
Yale University, New Haven, CT.
Intro: Kidney Transplant Recipients (KTRs) taking calcineurin inhibitors (CNIs) can experience varying drug toxicities. Less well studied compared to the metabolic consequences, many patients report…
2018 American Transplant Congress
Prolonged-Release Tacrolimus Dosing in De Novo Kidney Transplantation: Randomized, Open-Label, Pilot Study
Y. Kim,¹ Y. Chiang,² S. Kim,³ M. Kim,⁴ S. Park,⁵ S. Wu,⁶ K. Horita,⁷ Y. Nakashima,⁷ H. Jiang,⁸ D. Han.¹
¹Asan Medical Center, Seoul, Korea; ²Chang Gung Memorial Hospital-Linkou, Taoyuan City, Taiwan; ³Samsung Medical Center, Seoul, Korea; ⁴Severance Hospital, Seoul, Korea; ⁵Dongsan Medical Center, Daegu, Korea; ⁶Tri-Service General Hospital, Taipei City, Taiwan; ⁷Astellas Pharma, Inc., Tokyo, Japan; ⁸Astellas Pharma, Inc., Maao, Singapore.
A multicenter, randomized, open-label, parallel-group, pilot, 52-wk study in Asian countries that assessed renal function, efficacy, and safety of low vs standard-dose prolonged-release tacrolimus (PRT)…
2018 American Transplant Congress
Regulation of NK Cell Cytotoxicity by TEC Expression of Clr Proteins in Kidney Ischemia Reperfusion Injury (IRI)
B. Fuhrmann,^1,5 D. Lian,⁵ Z. Yin,⁵ S. Ma,^4,5 J. Arp,⁵ Z. Zhang,^2,3,4,5 A. Jevnikar.^1,3,4,5
¹Microbiology and Immunology, Western University, London, Canada; ²Pathology, Western University, London, Canada; ³Medicine, Western University, London, Canada; ⁴Multi-Organ Transplant Program, London Health Sciences Centre, London, Canada; ⁵Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, Canada.
Background: Kidney tubular epithelial cells (TEC) may negatively regulate NK cell activation and cytotoxic capacity by surface expression of a novel class of C-type lectin-related…
2018 American Transplant Congress
High Calcineurin Inhibitor Intra Patient Variability is Associated with Early Renal Allograft Inflammation, Chronicity and Loss
A. Sharma,¹ A. Cherukuri,² R. Mehta,¹ P. Sood,¹ S. Hariharan.¹
¹Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.
High CNI IPV has been associated with poor kidney allograft outcomes, albeit in small limited studies. We evaluated effect of CNI IPV (the degree of…
2018 American Transplant Congress
Increased Pre-Transplant Rejection-Risk Measured with Allospecific T-Cells Predicts Delayed Immunosuppression Minimization in Children with Intestine Transplantation.
K. Soltys, C. Ashokkumar, G. Mazariegos, G. Bond, M. Ningappa, A. Khanna, A. Ganoza, Q. Sun, R. Sindhi.
Pediatric Abdominal Transplant, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA.
BACKGROUND: Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) are used clinically to predict acute cellular rejection (ACR) after intestine transplantation (ITx) in children <21 years old within…
2018 American Transplant Congress
A Population Based Study of Incidence of Post Kidney Transplant Malignancies
D. Sexton,¹ J. O'Neill,² P. O'Kelly,¹ S. Murray,¹ S. Deady,³ E. O'Leary,³ P. Morris,⁴ P. Conlon.¹
¹Department of Nephrology & Transplantation, Beaumont Hospital Dublin, Royal College of Surgeons Ireland, Dublin, Ireland; ²Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland; ³National Cancer Registry Ireland, Cork, Ireland; ⁴Department of Oncology, Beaumont Hospital, Dublin, Ireland.
IntroductionWe aimed to report national standardised incidence for malignancy post transplant compared to the general population stratified by solid organ categories. In this study we…
2018 American Transplant Congress
The Risk Factors of Acute Rejection in Patients with BK Nephropathy after the Reduction of Immunosuppression
C. Baek,¹ H. Kim,¹ W. Yang,¹ D. Han,² S-.K. Park.¹
¹Department of Internal Medicine, Division of Nephrology, Asan Medical Center, Seoul, Republic of Korea; ²Department of Surgery, Asan Medical Center, Seoul, Republic of Korea.
Background: BK nephropathy (BKN) affects graft function and increases the risk of graft failure. The reduction of immunosuppression is the main treatment for BKN. However,…